论文部分内容阅读
目的:探讨肾小球硬化大鼠蛋白尿与转化生长因子β1(TGF-β1)相关性以及活血补肾复方的干预作用。方法:采用单侧肾切除加注射阿霉素造模法,将实验动物随机分为正常对照组、模型组、西药对照组、中药防治组和中药治疗组。动态观察24 h尿蛋白量,检测血浆和肾组织中TGF-β1的含量。结果:蛋白尿在肾小球硬化大鼠模型中呈现出一定的变化规律;随着肾小球硬化的进展,血清TGF-β1水平表现为升高趋势;活血补肾复方能够降低肾小球硬化初期尿蛋白量。结论:大鼠肾小球硬化模型组尿蛋白持续升高,血清和肾组织中TGF-β1含量持续升高,活血补肾复方能够降低肾小球硬化大鼠初期(1~8周)蛋白尿量。
Objective: To investigate the correlation between proteinuria and transforming growth factor-β1 (TGF-β1) in rats with glomerulosclerosis and the intervention of Huoxue Bushen compound. Methods: Using unilateral nephrectomy and adriamycin injection, the experimental animals were randomly divided into normal control group, model group, western medicine control group, Chinese medicine prevention and treatment group and Chinese medicine treatment group. The 24 h urinary protein level was dynamically observed and the plasma and renal TGF-β1 levels were measured. RESULTS: Proteinuria showed a pattern of changes in a rat model of glomerulosclerosis. With the progress of glomerulosclerosis, the serum TGF-β1 level showed an increasing trend; and Huoxue Bushen compound could reduce the initial glomerulosclerosis. Urine protein amount. Conclusion: Urinary protein in the glomerular sclerosis model group continued to increase, and serum and renal TGF-β1 levels continued to increase. Huoxue Bushen compound can reduce the initial (1 to 8 weeks) proteinuria in glomerulosclerotic rats. .